Cell Therapy Market

Market Overview:

Global Cell Therapy Market is valued at USD 10.1 Billion in 2021 and is projected to attain a value of USD 16.1 Billion by 2028 at a CAGR of 12.10% during the forecast period, 2022–2028. The growing number of clinical trials for cell-based therapeutics is driving the industry. As a result, there has been a significant increase in global investment in research and clinical translation. The presence of government and commercial funding agencies that are continually issuing grants to support projects at various phases of clinical trials can be ascribed to the growing number of ongoing clinical studies. In addition, advances in the field of regenerative medicine are projected to lead to more effective treatment options for chronic illnesses. Several firms in emerging areas, such as Canada, are at the vanguard, attempting to profit on the market for Cell Therapy s untapped potential.

Most businesses have been working on the development of cell-based therapeutics for COVID-19 treatment, the impact of the COVID-19 pandemic on the Cell Therapy Market is projected to be enormous. Because most pharmaceutical, biotechnology, and research organisations have been concentrating on the development of cell therapy-based treatment against COVID-19, the impact of COVID-19 is likely to have a beneficial impact on the studied market.

Rising Government Investments in Cell-Based Research

The demand for novel, better medicines for diseases like cancer and cardiovascular disease has led in an increase in general research effort, as well as financing for cell-based research. The Stem Cell Therapies Mission, a 10-year roadmap for stem cell research in Australia, was released by the Australian government in November 2019. Under the Medical Research Future Fund (MRFF), the project would grant USD 102 million (AU$150 million) to encourage stem cell research in order to develop novel medicines. The National Institutes of Health (NIH) has greatly boosted funding for the development of cell treatments in the United States over the years. The good financing situation is boosting demand for Cell Therapy research equipment, media, reagents, and accessories.

Dearth of Skilled Professionals

Despite technological advancements and product development over the last decade, the market has been hampered by a shortage of skilled workers who can operate sophisticated instruments like flow cytometers and multi-mode readers. Flow cytometers and spectrophotometers, which are technologically modern and very complicated, produce a wide range of data outputs that require skill to analyse and review. There remains, nevertheless, a global demand-supply gap for trained people.

Market Segmentation:

Global Cell Therapy Market is segmented on the basis of Use-Type into Clinical Use and Research Use. Based on Type, the Cell Therapy market segmented into Autologous Therapies and Allogenic Therapies. Based on region, the Cell Therapy market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

North America to Continue Dominating the Cell Therapy Market

In 2020, North America dominated the Cell Therapy market over the forecast period. The market is expected to rise due to the existence of a high number of centres and institutes working in stem cell treatment research and development accounts for the regions large share. Five of the eight top colleges in the world are headquartered in the United States, including Stanford Universitys Institute for Stem Cell Biology and Regenerative Medicine, Harvard Universitys Harvard Stem Cell Institute, and Yale Universitys Yale Stem Cell Center.

{{Map_Revenue}}

Top Key Players:

Some of the players in the Cell Therapy Market is Kolon TissueGene, Inc.; Anterogen Co., Ltd.; JCR Pharmaceuticals Co., Ltd.; Castle Creek Biosciences, Inc.; The Future of Biotechnology, MEDIPOST; Osiris Therapeutics, Inc.; PHARMICELL Co., Ltd.; Tameika Cell Technologies, Inc.; Cells for Cells; NuVasive, Inc.; Vericel Corporation; Celgene Corporation, among others.

Recent Developments

• This year in January 2024, Kite Pharma received approval for a new CAR-T manufacturing process that will help speed up the turnaround times for Yescarta-related therapies. This approval will help shorten manufacturing time by 2 days, making it 5 days from the previous 7 days.
• Back again in January 2024, Fate Therapeutics announced the start of its new Phase I clinical trial in collaboration with Ono Pharmaceutical of solid tumour therapy. Chimeric antigen receptor (CAR) T-cell therapy is being used to treat solid tumours and this trial assesses its safety and tolerability among patients.
• October 2023, Aurion Biotech initiated a phase 1/2 clinical trial in the United States to evaluate its cell therapy aimed at treating corneal edema. This study marks a significant advancement in exploring innovative treatment options for this eye condition. The trials progression will be closely monitored as it seeks to demonstrate the therapys safety and efficacy in patients.
• October 2023, Nkarta, Inc. received FDA approval for its Investigational New Drug (IND) application to study NKX019, an allogeneic CAR NK cell therapy targeting CD19. This therapy aims to provide a novel treatment option for lupus nephritis, a challenging autoimmune condition. The approval marks a crucial step in advancing NKX019 towards clinical trials, where its effectiveness and safety will be assessed.
• June 2023, Vertex Pharmaceuticals Incorporated partnered with Lonza to establish a joint venture aimed at enhancing the production of Vertexs investigational stem cell therapies. This collaboration specifically targets treatments for Type 1 Diabetes (T1D), concentrating on the clinical trial programs VX-880 and VX-264. The initiative is expected to streamline manufacturing processes and support the advancement of these promising therapies.
• May 2023, Johnson & Johnson entered into a global collaboration and licensing agreement with Cellular Biomedicine Group to co-develop advanced CAR-T therapies. This partnership aims to innovate and enhance the effectiveness of CAR-T treatments, reflecting both companies' commitment to advancing cancer therapies. The collaboration is expected to accelerate the development of these next-generation therapies in the oncology space.
• March 2023, Adaptimmune Therapeutics plc and TCR2 Therapeutics announced a strategic partnership aimed at establishing a leading cell therapy organization focused on treating solid tumors. This alliance is designed to leverage each companys expertise and resources to advance innovative therapies in this challenging area of oncology. The collaboration reflects a shared commitment to improving treatment options and outcomes for patients with solid tumor cancers.

The Cell Therapy Market is segmented as follows:

The Cell Therapy Market is tabulated as follows: